Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TAS2R8 | Q9NYW2 | 7/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6306977 | 0.78 | L3MBTL1 (0.40) | L3MBTL1PDE10AALDH1A1MEN1KMT2A | |
| SCHEMBL6307242 | 0.78 | L3MBTL1 (0.40) | L3MBTL1HTTALDH1A1 | |
| SCHEMBL5662451 | 0.76 | L3MBTL1 (0.40) | L3MBTL1KMT2A | |
| SCHEMBL5665366 | 0.75 | L3MBTL1 (0.52) | L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL5663721 | 0.75 | FDPS (0.39) | L3MBTL1PDE10AERN1ALDH1A1KMT2A | |
| SCHEMBL6314594 | 0.73 | L3MBTL1 (0.38) | L3MBTL1HTTALDH1A1KDM4ELMNA | |
| SCHEMBL6309420 | 0.72 | L3MBTL1 (0.40) | L3MBTL1KDM4ELMNAMEN1KMT2A | |
| SCHEMBL6309425 | 0.72 | L3MBTL1 (0.40) | L3MBTL1HTTKDM4ELMNAMEN1 | |
| SCHEMBL6305868 | 0.71 | L3MBTL1 (0.40) | L3MBTL1ERN1LMNAMEN1KMT2A | |
| SCHEMBL6308413 | 0.71 | L3MBTL1 (0.38) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124586-A1 | Alpha-substituted arylalkyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2005-06-09 | — | — | US | claimed |
| EP-1482954-A4 | ALPHA-SUBSTITUTED ARYLALKYL PHOSPHONATE DERIVATIVES | ILEX PRODUCTS INC (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050124586-A1 | Alpha-substituted arylalkyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2005-06-09 | — | — | US | disclosed |
| EP-1482954-A2 | ALPHA-SUBSTITUTED ARYLALKYL PHOSPHONATE DERIVATIVES | Ilex Products, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003069302-A2 | ALPHA-SUBSTITUTED ARYLALKYL PHOSPHONATE DERIVATIVES | ILEX PRODUCTS, INC. (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124586-A1 | Alpha-substituted arylalkyl phosphonate derivatives | APOB, APOL1, LDLR | L3MBTL1 1215/4885TAS2R8 4661/4885PDE10A 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.